Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

Cell Transplant ◽

Pivotal Phase ◽

Biomarker Analysis ◽

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant

American Journal of Hematology ◽

10.1002/ajh.21449 ◽

2009 ◽

Vol 84 (8) ◽

pp. 484-487 ◽

Cited By ~ 48

Author(s):

Paul M. Barr ◽

Hillard M. Lazarus ◽

Brenda W. Cooper ◽

Mark D. Schluchter ◽

Ashok Panneerselvam ◽

...

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Phase Ii ◽

Stem Cell Transplant ◽

Phase Ii Study ◽

Cell Transplant ◽

Bryostatin 1 ◽

Non Hodgkin Lymphoma

Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma

Leukemia & Lymphoma ◽

10.3109/10428191003611428 ◽

2010 ◽

Vol 51 (4) ◽

pp. 641-649 ◽

Cited By ~ 5

Author(s):

Andrew P. Grigg ◽

Janey Stone ◽

Alvin D. Milner ◽

Anthony P. Schwarer ◽

Max Wolf ◽

...

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Phase Ii ◽

Poor Prognosis ◽

Stem Cell Transplant ◽

Phase Ii Study ◽

Cell Transplant ◽

Non Hodgkin Lymphoma

Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma

Indian Journal of Hematology and Blood Transfusion ◽

10.1007/s12288-021-01490-1 ◽

2021 ◽

Author(s):

Jaikumar Patel ◽

Akanksha Garg ◽

Kinnari Patel ◽

Kamlesh Shah ◽

Sanket Shah ◽

...

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Stem Cell Transplant ◽

Cell Transplant ◽

A Randomized Phase II Study of Amifostine Used As Stem Cell Protectant in Non-Hodgkin Lymphoma Patients Receiving Cisplatin-Based Salvage Chemotherapy Prior to Stem Cell Transplant

Journal of Hematotherapy & Stem Cell Research ◽

10.1089/152581601317210980 ◽

2001 ◽

Vol 10 (6) ◽

pp. 887-893 ◽

Cited By ~ 4

Author(s):

Christos Emmanouilides ◽

Mary Territo ◽

Jeffrey Andrey ◽

James Mason

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Phase Ii ◽

Stem Cell Transplant ◽

Phase Ii Study ◽

Salvage Chemotherapy ◽

Cell Transplant ◽

Non Hodgkin Lymphoma ◽

Randomized Phase Ii

Role of Salvage Radiation Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2012.04.007 ◽

2012 ◽

Vol 84 (3) ◽

pp. e329-e335 ◽

Cited By ~ 21

Author(s):

Jayant S. Goda ◽

Christine Massey ◽

John Kuruvilla ◽

Mary K. Gospodarowicz ◽

Woodrow Wells ◽

...

Keyword(s):

Radiation Therapy ◽

Stem Cell ◽

Hodgkin Lymphoma ◽

Stem Cell Transplant ◽

Cell Transplant ◽

Salvage Radiation Therapy ◽

Faculty Opinions recommendation of Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718026606.793482211 ◽

2013 ◽

Author(s):

Nelson Chao

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Stem Cell Transplant ◽

Cell Transplant ◽

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

European Journal of Cancer ◽

10.1016/j.ejca.2011.12.016 ◽

2012 ◽

Vol 48 (5) ◽

pp. 713-720 ◽

Cited By ~ 20

Author(s):

C. Sebban ◽

A. Lefranc ◽

L. Perrier ◽

P. Moreau ◽

D. Espinouse ◽

...

Keyword(s):

Stem Cell ◽

Cost Effectiveness ◽

Phase Ii ◽

Stem Cell Transplant ◽

Phase Ii Study ◽

Cell Transplant

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

Leukemia & Lymphoma ◽

10.3109/10428194.2013.820287 ◽

2013 ◽

Vol 55 (5) ◽

pp. 1053-1060 ◽

Cited By ~ 8

Author(s):

Simon J. Harrison ◽

Andy K. Hsu ◽

Paul Neeson ◽

Anas Younes ◽

Anna Sureda ◽

...

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Stem Cell Transplant ◽

Cell Transplant ◽

Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study

European Journal Of Haematology ◽

10.1111/ejh.12973 ◽

2017 ◽

Vol 99 (6) ◽

pp. 553-558 ◽

Cited By ~ 7

Author(s):

Paul J. Bröckelmann ◽

Erin A. Zagadailov ◽

Shelby L. Corman ◽

Viktor Chirikov ◽

Courtney Johnson ◽

...

Keyword(s):

United Kingdom ◽

Stem Cell ◽

Retrospective Study ◽

Hodgkin Lymphoma ◽

Stem Cell Transplant ◽

Brentuximab Vedotin ◽

Cell Transplant ◽

Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis

Current Medical Research and Opinion ◽

10.1185/03007995.2015.1048208 ◽

2015 ◽

Vol 31 (7) ◽

pp. 1377-1389 ◽

Cited By ~ 6

Author(s):

Vijayveer Bonthapally ◽

Hongbo Yang ◽

Rajeev Ayyagari ◽

Ruo-Ding Tan ◽

Sean Cai ◽

...

Keyword(s):

Overall Survival ◽

Stem Cell ◽

Hodgkin Lymphoma ◽

Median Overall Survival ◽

Stem Cell Transplant ◽

Meta Analysis ◽

Brentuximab Vedotin ◽

Cell Transplant ◽